181 related articles for article (PubMed ID: 10229966)
21. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
22. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
[TBL] [Abstract][Full Text] [Related]
23. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
24. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
25. COMT inhibitors: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S45-51. PubMed ID: 12211139
[No Abstract] [Full Text] [Related]
26. Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease.
Truong DD
Clin Interv Aging; 2009; 4():109-13. PubMed ID: 19503773
[TBL] [Abstract][Full Text] [Related]
27. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
Nyholm D; Johansson A; Lennernäs H; Askmark H
Eur J Neurol; 2012 Jun; 19(6):820-6. PubMed ID: 22136163
[TBL] [Abstract][Full Text] [Related]
28. Utility of tolcapone in fluctuating Parkinson's disease.
Stocchi F; De Pandis MF
Clin Interv Aging; 2006; 1(4):317-25. PubMed ID: 18046910
[TBL] [Abstract][Full Text] [Related]
29. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
Merello M; Lees AJ; Webster R; Bovingdon M; Gordin A
J Neurol Neurosurg Psychiatry; 1994 Feb; 57(2):186-9. PubMed ID: 8126502
[TBL] [Abstract][Full Text] [Related]
30. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
[TBL] [Abstract][Full Text] [Related]
31. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
[TBL] [Abstract][Full Text] [Related]
32. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
33. [COMT inhibitors].
Bornkessel B
Med Monatsschr Pharm; 1999 May; 22(5):138-41. PubMed ID: 10365553
[No Abstract] [Full Text] [Related]
34. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Sovijärvi A; Kaakkola S; Gordin A; Teräväinen H
Clin Neuropharmacol; 2001; 24(1):50-7. PubMed ID: 11290882
[TBL] [Abstract][Full Text] [Related]
35. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
[TBL] [Abstract][Full Text] [Related]
36. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.
Bonifati V; Meco G
Pharmacol Ther; 1999 Jan; 81(1):1-36. PubMed ID: 10051176
[TBL] [Abstract][Full Text] [Related]
37. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Kaakkola S
Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
[TBL] [Abstract][Full Text] [Related]
38. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
39. Entacapone in the treatment of Parkinson's disease.
Schrag A
Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
[TBL] [Abstract][Full Text] [Related]
40. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
